dr. kay discusses the role of ibrutinib in cll
Published 6 years ago • 457 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
1:20
dr. kay discusses the role of acalabrutinib in cll
-
1:04
dr. kay discusses combination strategies in cll
-
1:25
dr. wierda discusses the role of ibrutinib in cll
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
1:25
dr. kay on genetic investigations in chronic lymphocytic leukemia
-
0:51
dr. seymour on role of ibrutinib in cll
-
5:50
idelalisib in chronic lymphocytic leukemia
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:39
dr. woyach on the role of acalabrutinib in cll
-
1:01
dr. andreadis discusses the role of ibrutinib in dlbcl
-
7:19
acalabrutinib’s role in treating chronic lymphocytic leukemia
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:47
dr. barrientos on the role of acalabrutinib in cll